Immix Biopharma, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Immix announced interim Phase 2 results for NXC-201 (CAR-T therapy) in relapsed/refractory AL Amyloidosis across 45 patients: 89% complete response rate (40/45), with all 25 new patients either in CR or MRD-negative; 4 additional MRD-negative patients could push CR rate to 98% (44/45) if confirmed. No relapses, neurotoxicity, or enterocolitis observed. Final readout and BLA submission planned mid-2027.
Why this rating
Strong interim efficacy data materially de-risks lead program for $35.7M-cap biotech; upcoming BLA potential near-term catalyst, but binary regulatory outcome remains. Major catalyst for this size.
Price action (we called it positive)
before filing · preread $11.60 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.